27 results on '"Takahashi, M."'
Search Results
2. (1420) - Does HLA Mismatch Between Donors and Recipients Influence Postoperative Outcomes in Cadaveric Lung Transplants?
3. (598) - The Effect of Resolvin D1, Resolvin E1, and Their Precursors on Lung Ischemia-Reperfusion Injury.
4. (1265) - Surgical Strategy on Lung Transplantation for Kartagener's Syndrome.
5. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
6. (926) - Living-Donor Single-Lobe Lung Transplantation: A Single-Center Case Series.
7. (914) - Comparison of Perioperative Outcomes Between Living-Donor Lobar Lung Transplant Versus Deceased-Donor Lung Transplant.
8. (1046) - A Case of Living-Donor Lobar Lung Transplantation for Dyskeratosis Congenita.
9. (618) - Evidence of Alloimmune Activation Early After Lung Transplantation and its Impact on Graft Survival.
10. 189 (PB-096) Poster - Multicenter study to evaluate the efficacy and standardize radiofrequency ablation therapy for early breast cancer.
11. A0130 - Development of pT classification prediction system in UTUC using deep-learning.
12. P170 - Effect of HLA genotype on anti-PD-1 antibody treatment for advanced renal cell carcinoma.
13. 454P A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study.
14. (687) - Is Chronic Lung Allograft Dysfunction More Common After Lung Transplantation for Pulmonary Complications of Hematopoietic Stem Cell Transplantation?
15. (658) - Blockade of ICAM-1 and LFA-1 Early After Transplantation Prevents Acute Cellular Rejection and Fibrotic Progression in Allogeneic Murine Lung Transplantation Model.
16. LBA76 The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).
17. 101P The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer.
18. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC.
19. 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522.
20. The void fraction and frictional pressure drop of upward two-phase flow under high pressure brine condition.
21. 1224P Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08).
22. 256P Difference of immunological status and response to immune checkpoint inhibitor between recurrent and de novo stage IV HER2-negative breast cancer in NEWBEAT trial (WJOG9917BTR).
23. 1776P Immune microenvironment, homologous recombination deficiency and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: JBCRG22 TR.
24. P-56 A multicenter prospective translational study using circulating tumor DNA to identify acquired genomic alterations in recurrent gastric or gastroesophageal junction adenocarcinoma in patients who received curative-intent treatment (Liquid-GEAR).
25. O-13 Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08).
26. MYOTONIC DYSTROPHY: EP.234 Liver dysfunction and dyslipidemia in myotonic dystrophy type 1: a cross-sectional study using the national registry of Japan.
27. 277P Phase II randomized study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with HR-positive and HER2-negative advanced breast cancer (MERMAID) WJOG11318B.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.